Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection.

Fiche publication

Date publication

décembre 2018

Journal

Gut

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas

Tous les auteurs :
Hoogeveen RC, Robidoux MP, Schwarz T, Heydmann L, Cheney JA, Kvistad D, Aneja J, Melgaço JG, Fernandes CA, Chung RT, Boonstra A, Kim AY, Baumert TF, Timm J, Lewis-Ximenez LL, Tonnerre P, Lauer GM

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30580250

Résumé

Chronic HBV infection affects more than 250 million people worldwide and remains a global healthcare problem in part because we lack curative treatment. Sustained viral control requires HBV-specific T cells, but these become functionally impaired in chronic infection. Clinical evidence indicates that functional cure of HBV infection by the host immune response is feasible. Developing T cell-based therapies able to achieve functional cure will require identification of the requirements for a successful T cell response against HBV and the relative contribution of individual T cell specificities to HBV control.